KMS Medisurgi

How has been the historical performance of the KMS Medisurgi?

KMS Medisurgi has shown stable financial performance from March 2019 to March 2024, with increased total reserves and shareholder's funds, reduced long-term debt, and improved book value per share, despite reporting no profit before tax during the period. Total assets and liabilities remained consistent, indicating growth in equity while managing debt levels effectively.

Answer:<BR>The historical performance of KMS Medisurgi shows a consistent trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>KMS Medisurgi has maintained a stable share capital of Rs 3.30 crore from March 2019 to March 2024. Total reserves have increased from Rs 2.95 crore in March 2019 to Rs 4.36 crore in March 2024, indicating a positive trend in retained earnings. Shareholder's funds have also risen from Rs 6.25 crore in March 2019 to Rs 7.66 crore in March 2024. Long-term borrowings have decreased from Rs 1.13 crore in March 2019 to Rs 0.54 crore in March 2024, reflecting a reduction in debt levels. Total liabilities increased from Rs 10.54 crore in March 2019 to Rs 10.73 crore in March 2024, while total assets grew from Rs 10.54 crore to Rs 10.73 crore in the same period. The book value per share has improved from Rs 18.95 in March 2019 to Rs 23.22 in March 2024. However, the company reported no profit before tax from March 2020 to March 2023, with a notable cash flow from operating activities consistently at Rs 0.00 during these years. Overall, KMS Medisurgi has shown growth in its equity and asset base while managing to reduce its long-term debt.

how big is KMS Medisurgi?

As of Apr 05, KMS Medisurgi Ltd has a market capitalization of 40.00 Cr, classifying it as a Micro Cap company, with shareholder's funds of 7.66 Cr and total assets of 10.73 Cr; however, no recent financial data is available for the latest four quarters.

Market Cap: As of Apr 05, KMS Medisurgi Ltd has a market capitalization of 40.00 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: As of Apr 05, there is no valid Consolidated or Standalone financial data available for the latest four quarters, including Net Sales and Net Profit.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the reporting period of Mar'24. The Shareholder's Funds amount to 7.66 Cr, and the Total Assets are valued at 10.73 Cr.

Who are in the management team of KMS Medisurgi?

As of March 2022, the management team of KMS Medisurgi includes Rekha Devang Kanakia (Chairman & Managing Director), Kamlesh Chunilal Rajani, Hardik Rajnikant Bhatt, Pratik Pravin Tarpara (all Independent Directors), Sidddharth Kanakia, Rohan Devang Kanakia (Directors), and Sunny Gupta (Company Secretary & Compliance Officer). Each member contributes to the company's governance and strategic direction.

As of March 2022, the management team of KMS Medisurgi consists of the following individuals:<BR><BR>1. Rekha Devang Kanakia - Chairman & Managing Director<BR>2. Kamlesh Chunilal Rajani - Independent Director<BR>3. Hardik Rajnikant Bhatt - Independent Director<BR>4. Sidddharth Kanakia - Director<BR>5. Pratik Pravin Tarpara - Independent Director<BR>6. Rohan Devang Kanakia - Director<BR>7. Sunny Gupta - Company Secretary & Compliance Officer<BR><BR>Each member plays a crucial role in the governance and strategic direction of the company.

What does KMS Medisurgi do?

KMS Medisurgi Ltd is a micro-cap healthcare services company that manufactures and coats substrates with adhesive. It was incorporated in 1999 and became a public company in 2016, with a market cap of Rs 40 Cr.

Overview: <BR>KMS Medisurgi Ltd is a micro-cap company in the healthcare services industry that manufactures and undertakes job work of coating various substrates with adhesive.<BR><BR>History: <BR>KMS Medisurgi Limited was incorporated as "KMS Medisurgi Private Limited" on March 25, 1999, in Mumbai. The company converted into a public limited company and changed its name to "KMS Medisurgi Limited" on June 15, 2016. Revenue and profit data are not available for the latest quarter.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: Rs 40 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 41.00 <BR>Industry P/E: 24 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.11 <BR>Return on Equity: 7.89% <BR>Price to Book: 5.57<BR><BR>Contact Details: <BR>Address: 297/301 May Building Grou. Flr, Marine (East) Princess Street Mumbai Maharashtra : 400002 <BR>Tel: 91-22-66107700/66107722 <BR>Email: kms.medisurgi@gmail.com <BR>Website: http://www.kmsgroup.in

When is the next results date for KMS Medisurgi?

No Upcoming Board Meetings

Has KMS Medisurgi declared dividend?

No Dividend History Available

What is the technical trend for KMS Medisurgi?

As of April 15, 2024, KMS Medisurgi's technical trend is neutral, with the price stagnant at 125.00 and no significant movement in the 52-week high or low.

As of 15 April 2024, the technical trend for KMS Medisurgi has changed from mildly bullish to does not qualify. The current price is stagnant at 125.00, matching the previous close, with no movement in the 52-week high or low. Given the lack of significant price action and the absence of technical summary data, there is insufficient information to determine a clear bullish or bearish stance. The overall technical outlook is neutral.

Who are the peers of the KMS Medisurgi?

KMS Medisurgi's peers include Aspira Pathlab, Amkay Products, N G Industries, Bandaram Pharma, Deccan Healthcar, Medinova Diagno., Tejnaksh Health., GKB Ophthalmics, and Transgene Biotek. In terms of performance, Aspira Pathlab leads with a 1-year return of 64.58%, while KMS Medisurgi has a return of 0.80%.

Peers: The peers of KMS Medisurgi are Aspira Pathlab, Amkay Products, N G Industries, Bandaram Pharma, Deccan Healthcar, Medinova Diagno., Tejnaksh Health., GKB Ophthalmics, and Transgene Biotek.<BR><BR>Quality Snapshot: Excellent management risk is observed at Amkay Products and Shree Pacetronix, while Average management risk is found at KMS Medisurgi, N G Industries, and Bandaram Pharma, and the rest. Below Average management risk is noted at Aspira Pathlab, Deccan Healthcar, Tejnaksh Health., and GKB Ophthalmics, while Medinova Diagno. and Transgene Biotek do not qualify. Growth is Excellent at Bandaram Pharma, Average at KMS Medisurgi and N G Industries, Below Average at Aspira Pathlab, Amkay Products, Deccan Healthcar, Tejnaksh Health., and GKB Ophthalmics, and the rest do not qualify. Capital Structure is Good at KMS Medisurgi, N G Industries, Deccan Healthcar, Tejnaksh Health., and GKB Ophthalmics, Average at Aspira Pathlab and Amkay Products, Below Average at Bandaram Pharma, and the rest do not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Aspira Pathlab at 64.58%, while the peer with the lowest is Transgene Biotek at -49.45%. KMS Medisurgi's 1-year return is 0.80%, which is significantly lower than Aspira Pathlab's but higher than Transgene Biotek's. Additionally, several peers, including Deccan Healthcar, GKB Ophthalmics, and Shree Pacetronix, have negative six-month returns.

Who are the top shareholders of the KMS Medisurgi?

The top shareholders of KMS Medisurgi are Moni Diamonds Limited with 19.21% and Yagnesh Manaharlal Joshi as the highest public shareholder at 5.82%. Individual investors hold a total of 21.7%, with no mutual fund or foreign institutional investor holdings and no pledged promoter shares.

The top shareholders of KMS Medisurgi include Moni Diamonds Limited, which holds the highest stake at 19.21%. Additionally, Yagnesh Manaharlal Joshi is the highest public shareholder with a holding of 5.82%. Overall, individual investors collectively hold 21.7% of the company's shares. The company does not have any mutual fund or foreign institutional investor (FII) holdings, and there are no pledged promoter holdings.

Is KMS Medisurgi overvalued or undervalued?

As of September 16, 2025, KMS Medisurgi is considered very expensive and overvalued with a PE ratio of 41.75, an EV to EBIT ratio of 41.87, and a Price to Book Value of 5.45, underperforming the Sensex and raising concerns about its growth prospects.

As of 16 September 2025, the valuation grade for KMS Medisurgi has moved from risky to very expensive. The company is currently considered overvalued, with a PE ratio of 41.75, an EV to EBIT ratio of 41.87, and a Price to Book Value of 5.45. These figures suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, KMS Medisurgi's PE ratio is lower than Poly Medicure's 56.1 but higher than Blue Jet Health's 34.66, indicating a mixed competitive positioning. The PEG ratio stands at 0.00, which raises concerns about growth prospects relative to its valuation. Notably, while KMS Medisurgi has delivered a 1.2% return year-to-date, it has underperformed the Sensex, which has returned 5.43% in the same period, further reinforcing the notion of overvaluation.

Why is KMS Medisurgi Ltd falling/rising?

As of 02-Apr, KMS Medisurgi Ltd's stock price is stable at Rs 126.50, but it has declined consistently over the past eight weeks and is 4.58% away from its 52-week high. Despite outperforming its sector today, the stock's recent performance and erratic trading patterns indicate a cautious outlook.

As of 02-Apr, KMS Medisurgi Ltd's stock price is currently stable at Rs 126.50, showing no change (0.00%). Despite this stability, the stock has experienced a consistent decline over the past eight weeks, generating 0% returns during this period. Additionally, it has fallen every month for the last six weeks. <BR><BR>In terms of performance relative to the market, the stock has outperformed its sector by 3.03% today, although the broader medical equipment sector has seen a decline of -3.03%. The stock is also trading above its moving averages, which indicates a relatively strong position compared to its historical performance. However, it is important to note that KMS Medisurgi Ltd is 4.58% away from its 52-week high of Rs 132.3, suggesting that while it has potential for growth, it has not capitalized on this in recent weeks.<BR><BR>Investor participation appears to be stable, with a delivery volume that has not changed against the 5-day average, indicating consistent interest in trading the stock. However, the erratic trading pattern, with the stock not trading on 5 out of the last 20 days, may contribute to uncertainty among investors.<BR><BR>Overall, while the stock is not currently falling in price, its recent history of consistent weekly and monthly declines, alongside broader sector challenges, suggests a cautious outlook for KMS Medisurgi Ltd.

Which are the latest news on KMS Medisurgi?

Which are the latest news on KMS Medisurgi?